Posted 2/26/2015 11:43 AM (GMT -6)
It is not clear but it appears that this is updated information from a Phase I trial that reported first results in 2012. The trial started some years before that. The men on this trial had only one option at the time, docetaxel. Those who survived until 2012 and later had Abi, Jevtana, Provenge, Xtandi, and Xofigo added to their options for use after they left the trial. This means that the survival cannot be placed on the trial drugs alone. Such are Phase I trials.
We live in a time when new drugs are coming with some regularity. How wonderful that is.